ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

STRO Sutro Biopharma Inc

1.94
0.06 (3.19%)
Pre Market
Last Updated: 13:16:43
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sutro Biopharma Inc NASDAQ:STRO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.06 3.19% 1.94 1.88 1.94 2,312 13:16:43

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

04/11/2024 9:05pm

GlobeNewswire Inc.


Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations at the 15th Annual World ADC Conference, taking place in San Diego, November 4-6, 2024.

Presentation Details:

  • Development of Dual-Payload Antibody Drug Conjugates 
    • Presenter: Daniel Calarese, Ph.D.
    • Date/Time: November 4, 2024, 2:00pm PT
  • Showcasing Clinical Update & Learnings for Luvelta Targeting Folate Receptor
    • Presenter: Hanspeter Gerber, Ph.D.
    • Date/Time: November 5, 2024, 11:30am PT
  • Characterizing ADC Safety & Activity in Preclinical Development of STRO-004 
    • Presenter: Alice Yam, Ph.D.
    • Date/Time: November 5, 2024, 2:00pm PT 
  • Leveraging Cell-Free Protein Synthesis for Site- Specific Conjugation to Enhance ADC Therapeutic Index 
    • Presenter: Gang Yin, Ph.D.
    • Date/Time: November 5, 2024, 2:30pm PT
  • Optimizing High DAR & Dual Payload ADCs: Discovery of Hydrophilic β-glu Cleavable Linker Payloads for Superior Efficacy and Safety 
    • Presenter: Krishna Bajjuri, Ph.D.
    • Date/Time: November 6, 2024, 3:00pm PT

Following the event, the content will be made available in the Clinical/Scientific Presentation and Publication Highlights section of Sutro Biopharma’s website at www.sutrobio.com.

About Sutro Biopharma Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Contact
Emily White
Sutro Biopharma
(650) 823-7681        
ewhite@sutrobio.com

1 Year Sutro Biopharma Chart

1 Year Sutro Biopharma Chart

1 Month Sutro Biopharma Chart

1 Month Sutro Biopharma Chart

Your Recent History

Delayed Upgrade Clock